Vivjoa

(Oteseconazole)

Phase 2

MMycovia Pharmaceuticals Inc.

Vivjoa is one of 3 small molecule programs targeting Coccidioidomycosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

CoccidioidomycosisNot yet recruiting

CoccidioidomycosisPhase 2

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Coccidioidomycosis

#DrugCompanyPhaseTrials

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 2

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

—3

Vivjoa

MMycovia Pharmaceuticals Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Coccidioidomycosis

NCT07804368

Clinical

Trials by Indication[1]

Coccidioidomycosis1 trial

Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi

Not yet recruiting·UUniversity of Minnesota·Phase 2·NCT07804368·30 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 26, 2022

VIVJOA

NDA NDA215888

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oteseconazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oteseconazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oteseconazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA215888). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Mycovia Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: MMycovia Pharmaceuticals Inc.

Vivjoa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Coccidioidomycosis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News